On September 3, 2024 Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, reported that Paul Peter Tak, MD, PhD, FMedSci, Candel’s President and Chief Executive Officer, will present at the 26th Annual Global Investment Conference being held in-person and virtually on September 9-11, 2024 (Press release, Candel Therapeutics, SEP 3, 2024, View Source [SID1234646316]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Time: Available from 7:00 a.m. ET onwards
Date: Monday, September 9, 2024
Webcast Link: View Source

A webcast of the H.C. Wainwright presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section on candeltx.com. A replay of the webcast will be archived for up to 90 days following the session date.

On September 3, 2024 Indaptus Therapeutics, Inc. (Nasdaq: INDP) reported that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26 th Annual Global Investment Conference. The conference is being held on September 9 – 11, 2024 at the Lotte New York Palace Hotel (Press release, Indaptus Therapeutics, SEP 3, 2024, View Source;qmodStoryID=5871576807142026 [SID1234646315]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Date: September 9, 2024
Time: Available on-demand starting at 7:00 AM Eastern Time
Webcast Link: View Source
A live webcast of the presentation can be accessed on the investor relations section of the Indaptus website. A replay of the webcast will be archived and available following the event for approximately 90 days.
View Source

Mr. Meckler will be available for one-on-one meetings throughout the conference. To request a meeting and to register for the conference, click below:

View Source

On September 03, 2024 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, reported that members of its management team will deliver two presentations at The Promise of Interleukin-2 Therapy Conference, taking place September 4-7, 2024 in Paris, France. (Press release, Cue Biopharma, SEP 3, 2024, View Source [SID1234646313]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details
Date and Time: Friday, September 6, 2024, 4 p.m. CET
Presentation Title: CUE-401: A Novel IL-2/TGF-beta fusion protein for the induction & expansion of FOXP3+ regulatory T Cells
Presenter: Steven Quayle, Ph.D., vice president & head, Biology Research & Translational Medicine, Cue Biopharma

Dr. Quayle will present preclinical data on our first-in-class bispecific fusion protein, CUE-401, which induces and expands regulatory T cells (Tregs) through the co-delivery of interleukin 2 (IL-2) and transforming growth factor beta (TGF-β), and how this approach differentiates from other Treg-directed therapies.

Date and Time: Saturday, September 7, 2024, 9 a.m. CET
Presentation title: Clinical safety and efficacy of TCR-specific engagers that selectively target IL-2 to tumor-specific T cells
Presenter: Matteo Levisetti, M.D., chief medical officer, Cue Biopharma

Dr. Levisetti will discuss how the company’s lead oncology programs CUE-101 and CUE-102, representative of the CUE-100 series of Immuno-STAT biologics, enable selective targeting of the cytokine IL-2 to tumor specific T cells for enhanced efficacy and safety profiles.

On September 3, 2024 Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, reported that the first patient has been dosed in its first-in-human Phase 1 trial of Descartes-15, the Company’s next-generation autologous anti-B cell maturation antigen (BCMA) mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) (Press release, Selecta Biosciences, SEP 3, 2024, View Source [SID1234646311]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Advancement of Descartes-15 into the clinic marks an important step forward in our mission to deliver innovative mRNA cell therapies to patients with autoimmune diseases," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. "We believe that Descartes-15, which was designed leveraging our novel mRNA platform, could serve as a highly potent next-generation cell therapy with the ability to be dosed in the outpatient setting without preconditioning chemotherapy. We look forward to advancing this important program into development for autoimmune indications with high unmet need."

Descartes-15 is designed to have predictable and controllable pharmacokinetics, including technological advances that enhance CAR stability even in the presence of target-driven suppression of CAR. Similar to Descartes-08, the Company’s lead product candidate, Descartes-15 is designed to be administered without preconditioning chemotherapy and does not use integrating vectors. Relative to Descartes-08, Descartes-15 has been observed to achieve an approximately ten-fold increase in CAR expression and selective target-specific killing in preclinical studies.

The Phase 1 dose escalation trial (NCT06304636) will assess the safety and tolerability of outpatient Descartes-15 administration in patients with multiple myeloma. Following the Phase 1 dose escalation trial, the Company expects to subsequently assess Descartes-15 in autoimmune indications.

On September 3, 2024 Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, reported that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York (Press release, Arbutus Biopharma, SEP 3, 2024, View Source [SID1234646312]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

-H.C. Wainwright 26th Annual Global Investment Conference: Formal Presentation on September 9, 2024 at 8:00 am ET
-Baird Global Healthcare Conference: Fireside Chat on September 10, 2024 at 8:30 am ET
To access the live webcast of the presentation and fireside chat please visit: View Source An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.